O

Option Care Health

Largest independent home infusion therapy provider

Director – Chronic Practice Sales Liaison

Full-TimeUpdated on 10/23/2026
$126.5k - $210.9k
Expert
Bachelor's, Master's
Itasca, IL, USA
In Person
Sales & Account ManagementField Sales

About the job

Requirements
  • A bachelor's degree is required.
  • At least 10 years of healthcare, specialty pharmacy, infusion, biotech, pharmaceutical, or provider-facing commercial leadership experience is required.
  • At least 5 years of experience leading national or regional field teams is required.
  • Demonstrated success driving referral growth and provider engagement is required.
  • Strong financial, operational, and business planning acumen is required.
  • Experience managing complex cross-functional initiatives is required.
  • Proven ability to lead in a matrixed healthcare environment is required.
Responsibilities
  • Develop and execute the national Chronic Practice Liaison strategy in alignment with enterprise growth objectives.
  • Identify and prioritize high-value referral sources, strategic accounts, and growth opportunities.
  • Drive referral volume, patient starts, revenue, and gross profit growth across targeted chronic therapies.
  • Partner with Specialty Sales, Area Sales Directors, and Regional Vice Presidents to optimize account ownership and growth plans.
  • Establish market penetration strategies for health systems, integrated delivery networks, academic medical centers, physician groups, and specialty practices.
  • Build executive-level relationships with key referral sources and strategic provider accounts.
  • Serve as the escalation point for complex provider concerns and access barriers.
  • Develop provider engagement programs that strengthen loyalty and increase referral utilization.
  • Ensure consistent execution of account planning, provider business reviews, and growth initiatives across markets.
  • Lead initiatives to improve referral acceptance, conversion rates, and patient starts.
  • Partner with Intake, Patient Liaisons, Pharmacy Operations, and Revenue Cycle teams to reduce friction throughout the patient journey.
  • Analyze referral leakage and implement corrective action plans.
  • Drive improvements in turnaround times, authorization performance, and time-to-treatment metrics.
  • Recruit, develop, and retain a high-performing Chronic Practice Liaison team.
  • Create performance standards, coaching strategies, and individualized development plans.
  • Foster a culture of accountability, collaboration, customer service, and continuous improvement.
  • Establish clear productivity expectations and performance metrics.
  • Collaborate with Operations, Clinical Services, Pharmacy, Nursing, Finance, Analytics, and Technology teams.
  • Translate field insights into operational and strategic improvements.
  • Participate in annual operating planning and forecasting processes.
  • Support implementation of technology and workflow enhancements that improve provider and patient experiences.
  • Establish key performance indicators and performance dashboards.
  • Monitor referral trends, conversion performance, account growth, provider risk indicators, and patient progression metrics.
  • Use data-driven insights to guide resource allocation and territory optimization.
  • Deliver regular business reviews to executive leadership.
  • Be accountable for referral volume growth, patient starts growth, net revenue growth, gross profit growth, and market share expansion.
  • Be accountable for referral conversion rate, no-go rate reduction, time-to-treatment, prior authorization success rate, and order completion rate.
  • Be accountable for provider retention, strategic account growth, provider satisfaction, and health system penetration.
  • Be accountable for employee engagement, team retention, productivity per Chronic Practice Liaison, and succession bench strength.
Desired Qualifications
  • Experience in specialty pharmacy, home infusion, ambulatory infusion center, or buy-and-bill environments is preferred.
  • Experience with chronic therapies such as immunoglobulin, neurology, rheumatology, gastroenterology, and rare and orphan therapies is preferred.
  • Knowledge of reimbursement, payer access, prior authorizations, and specialty pharmacy operations is preferred.
  • A master's degree is preferred.

About the company

Option Care Health delivers infusion therapies at home and other alternate-site locations across the United States, supported by over 7,000 teammates including about 4,500 clinicians. Clinicians visit patients at home or approved sites to administer therapies, manage care, and coordinate with care teams under strong clinical leadership and national scale. It stands out as the largest independent infusion provider with nationwide reach and a robust clinical workforce, enabling scalable home and alternate-site infusion rather than hospital-only care. The goal is to elevate standards of care and reimagine the infusion care experience by expanding access, improving outcomes, and delivering compassionate, clinically driven service.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Bannockburn, Illinois

Founded

1979

Get referred to Option Care Health

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 29, 2026 Q2 revenue reached $1.44 billion, while acute therapy and IG Neuro strengthened.
  • Management stabilized CID patient census in Q2 2026 and kept full-year revenue guidance unchanged.
  • The company repurchased $150 million in Q2 2026, signaling confidence and shareholder-return capacity.

What critics are saying

  • August 2026 guidance still bakes in a 600-basis-point CID revenue headwind and $55 million gross profit hit.
  • July 29, 2026 Q2 buyback of $150 million masks weak top-line momentum and analyst skepticism.
  • Biosimilar erosion and payer reverification pressure can permanently shrink chronic volumes if retention stays broken.

What makes Option Care Health unique

  • Option Care Health leads U.S. independent home and alternate-site infusion, with nationwide clinician density.
  • Its payer, biopharma, and prescriber relationships create switching costs across chronic and acute therapies.
  • August 27, 2026 guidance shows durable cash generation, with at least $320 million operating cash flow.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Paid Time Off
  • Bonding Time Off
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Health Savings Account/Flexible Spending Account
  • Flexible Spending Accounts
  • Tuition Reimbursement
  • Family Support
  • Mental Health Support

Company News

AD HOC NEWS
Oct 15th, 2026
McKesson commits $1.4B for 49% stake in Option Care at $5.8B valuation

McKesson will invest $1.4 billion for a 49% minority stake in Option Care Health, under an agreement announced on October 6, 2026. The deal values Option Care at an enterprise value of $5.8 billion. Clayton, Dubilier & Rice will hold about 51%. Option Care will stay separately managed, while McKesson keeps a framework to acquire the remaining interest later, subject to conditions and regulatory approvals. In its first fiscal 2027 quarter, McKesson reported revenue of $105.38 billion, up 7.7% year on year, and adjusted earnings per share of $9.93. It will report second-quarter results on November 4, 2026.

Yahoo Finance
Oct 6th, 2026
McKesson and Clayton Dubilier & Rice near $5B deal to acquire Option Care Health

Option Care Health shares jumped 33.2% in pre-market trading after the Financial Times reported McKesson and Clayton Dubilier & Rice are nearing a transaction valued at over $5 billion to acquire the alternate site health provider. According to the report, the deal would involve the two firms partnering to buy the infusion services provider, which they view as undervalued. Large-scale buyout discussions typically drive market optimism as investors anticipate acquisition premiums. The move is significant for Option Care Health, whose shares have experienced 13 movements greater than 5% over the past year. At $31.03 per share, the stock is trading 15.2% below its 52-week high but remains down 3.8% year-to-date.

Central Charts
Oct 6th, 2026
CD&R and McKesson Corporation Sign Agreement to Acquire Option Care Health

CD&R, McKesson Corporation (NYSE: MCK) (“McKesson”), and Option Care Health, Inc. (Nasdaq: OPCH) (“Option Care Health”) announced today that they have

Yahoo Finance
Jul 29th, 2026
Option Care Health Q2 beats expectations with $1.4B revenue, narrows full-year guidance

Option Care Health reported second-quarter 2026 results that exceeded expectations. Revenue rose 7% sequentially to $1.4 billion, whilst adjusted EBITDA increased 12% to $117.5 million and adjusted EPS reached $0.45. Operating cash flow totalled $184 million. Acute therapies posted high-single-digit organic growth, while chronic revenue improved sequentially as the CID portfolio began to stabilise. However, CID-related pressure is expected to reduce 2026 revenue by roughly 600 basis points and gross profit by $55 million. The home and alternate-site infusion provider maintained its full-year revenue guidance at $5.675 billion to $5.775 billion. Adjusted EBITDA guidance was narrowed to $480 million to $495 million, and adjusted EPS guidance to $1.85 to $1.92. The company repurchased $150 million of shares, nearly 5% of shares outstanding.

Yahoo Finance
Jul 29th, 2026
Option Care Health reports $1.44B Q2 revenue, up 1.9%, and raises $150M share buyback

Option Care Health, the largest independent provider of home and alternate site infusion services in the US, reported second quarter 2026 results. Net revenue reached $1.44 billion, up 1.9% year-over-year. The company posted net income of $53.9 million, up 6.7%, with diluted earnings per share of $0.35, up 12.9%. Adjusted EBITDA grew 3.0% to $117.5 million. The company repurchased $150 million of outstanding shares during the quarter. For full year 2026, Option Care Health expects net revenue between $5.68 billion and $5.78 billion, with adjusted diluted earnings per share of $1.85 to $1.92. The company forecasts adjusted EBITDA of $480 million to $495 million and operating cash flow of at least $320 million.